James N Kochenderfer, M.D.

Fludarabine

8 trials

phase_1phase_1_2

fludarabine phosphate

Leukapheresis

Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells

Individual Patient TCR-Transduced PBL

Allogeneic stem cell transplant

Rimiducid

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

+11 more interventions

19 unique interventions4 categories

Analytics

Trial Phases

Phase 110

Phase 21

Trial Status

Completed6

Recruiting2

Terminated1

Other2

Role Distribution

Principal Investigator11

PI Rate100%

Activity Timeline

Clinical Trials (11)

NCT06364423Phase 1/2Recruiting

Acute Lymphoblastic LeukemiaB-Cell Chronic Lymphocytic LeukemiaB-Lymphocytic Leukemia, Chronic+4 more

PrincipalinvestigatorStart date: 2024-09-03

NCT05797233Phase 1Active Not Recruiting

Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

B-Cell Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaLymphoma, B-Cell

PrincipalinvestigatorStart date: 2023-08-28

NCT04160195Phase 1Terminated

T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

B-Cell Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaLymphoma, B-Cell+1 more

PrincipalinvestigatorStart date: 2019-12-20

NCT03958656Phase 1Completed

T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

Myeloma-MultipleMyeloma, Plasma-Cell

PrincipalinvestigatorStart date: 2019-06-13

NCT03602612Phase 1Completed

T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma

Myeloma-MultipleMyeloma, Plasma-Cell

PrincipalinvestigatorStart date: 2018-09-14

NCT03049449Phase 1Completed

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

Enteropathy-Associated T-Cell LymphomaLymphoma, Extranodal NK-T-CellLymphoma, Large B-Cell, Diffuse+2 more

PrincipalinvestigatorStart date: 2017-03-17

NCT02659943Phase 1Completed

T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies

Lymphoma, B-CellLymphoma, Non-hodgkins

PrincipalinvestigatorStart date: 2016-01-21

NCT02473757Enrolling By Invitation

Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies

Hematologic MalignanciesLeukemia, B-cellLyphoma, B-Cell+1 more

PrincipalinvestigatorStart date: 2015-09-24

NCT02215967Phase 1Completed

Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma

Myeloma-MultipleMyeloma, Plasma-Cell

PrincipalinvestigatorStart date: 2014-08-12

NCT01087294Phase 1Completed

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Leukemia, B-cellLymphoma, B-CellLymphoma, Hodgkins+1 more

PrincipalinvestigatorStart date: 2010-08-04

Showing 10 of 11 trials

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Lymphoma, B-Cell4 Multiple Myeloma4 Leukemia, Lymphocytic, Chronic, B-Cell3 Lymphoma, Non-Hodgkin3 Precursor Cell Lymphoblastic Leukemia-Lymphoma2 Hematologic Neoplasms2 Leukemia, B-Cell2 Myelodysplastic Syndromes1

Affiliations

National Cancer Institute (NCI)

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

24 trials

Shared therapeutic areas:

Multiple MyelomaLeukemia, Myeloid, AcuteLymphoma, B-Cell+5 more

Worked with same sponsors:

Multiple MyelomaLymphoma, Non-HodgkinLeukemia, Myeloid, Acute+4 more

Similarity Score13%

Arnon Nagler, MD

Chaim Sheba Medical Center

12 trials

Shared therapeutic areas:

Similarity Score12%

Yves Beguin, MD, PhD

CHU-ULg

7 trials

Shared therapeutic areas:

Hematologic NeoplasmsPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell+4 more

Similarity Score12%

Helen Heslop, MD

Baylor College of Medicine

17 trials

Shared therapeutic areas:

Lymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell+3 more

Similarity Score10%

Jae Park, MD

Memorial Sloan Kettering Cancer Center

17 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLymphoma, B-CellLeukemia, Lymphocytic, Chronic, B-Cell+2 more

Worked with same sponsors:

Leukemia, Myeloid, AcuteMyelodysplastic SyndromesHematologic Neoplasms+2 more

Similarity Score8%

Qifa Liu

Nanfang Hospital, Southern Medical University

33 trials

Shared therapeutic areas:

Similarity Score8%

Areej El-Jawahri, MD

Massachusetts General Hospital

21 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteHematologic NeoplasmsMultiple Myeloma+1 more

Worked with same sponsors:

Multiple MyelomaLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma+1 more

Similarity Score7%

David Avigan, MD

Beth Israel Deaconess Medical Center

17 trials

Shared therapeutic areas:

Worked with same sponsors:

Myelodysplastic SyndromesLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-Lymphoma+1 more

Similarity Score7%

Guillermo Garcia-Manero, MD

M.D. Anderson Cancer Center

18 trials

Shared therapeutic areas:

Similarity Score7%

Jorge Cortes, MD

M.D. Anderson Cancer Center

24 trials

Shared therapeutic areas:

Leukemia, Myeloid, AcuteMyelodysplastic SyndromesPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Worked with same sponsors: